{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:11:00Z","timestamp":1790727060117,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100032718","name":"Kura Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32CA009512-35"],"award-info":[{"award-number":["5T32CA009512-35"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["WO\/2017\/132398A1"],"award-info":[{"award-number":["WO\/2017\/132398A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.trecan.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:32:35Z","timestamp":1751545955000},"page":"889-900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advances in menin inhibition in acute myeloid leukemia"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-2071","authenticated-orcid":false,"given":"Leora","family":"Boussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng F.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.06.002_bb0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.trecan.2025.06.002_bb0010","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2025.06.002_bb0015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/leu.2012.356","article-title":"The role of HOX genes in normal hematopoiesis and acute leukemia","volume":"27","author":"Alharbi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2025.06.002_bb0020","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0025","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.06.002_bb0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/378505a0","article-title":"Altered Hox expression and segmental identity in Mll-mutant mice","volume":"378","author":"Yu","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.06.002_bb0035","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.trecan.2025.06.002_bb0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.2024026232","article-title":"Menin inhibitors in the treatment of acute myeloid leukemia","volume":"145","author":"Huls","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2025.06.002_bb0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2025.06.002_bb0055","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0060","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2025.06.002_bb0065","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ajh.26989","article-title":"NPM1-mutated acute myeloid leukemia: new pathogenetic and therapeutic insights and open questions","volume":"98","author":"Falini","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.trecan.2025.06.002_bb0070","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.06.002_bb0075","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.06.002_bb0080","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2025.06.002_bb0085","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.celrep.2017.05.005","article-title":"RUNX1-ETO and RUNX1-EVI1 differentially reprogram the chromatin landscape in t(8;21) and t(3;21) AML","volume":"19","author":"Loke","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2025.06.002_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1256043","article-title":"The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation","volume":"13","author":"Shen","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2025.06.002_bb0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.trecan.2025.06.002_bb0100","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","article-title":"NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","volume":"118","author":"Hollink","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0105","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.06.002_bb0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3324\/haematol.2010.029660","article-title":"Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia","volume":"96","author":"Balgobind","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.trecan.2025.06.002_bb0115","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/biomedicines11030821","article-title":"Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia","volume":"11","author":"G\u00f3recki","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.trecan.2025.06.002_bb0120","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.06.002_bb0125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2024-194384","article-title":"Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0130","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1056\/NEJMc2404110","article-title":"Response and resistance to menin inhibitor in UBTF-tandem duplication AML","volume":"390","author":"Tiong","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.06.002_bb0135","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.trecan.2025.06.002_bb0140","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: first-in-human Phase 1\/2 study of the menin-MLL Inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0150","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2024-198959","article-title":"A first-in-human Phase 1\/2 study of the menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2025.06.002_bb0160","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","article-title":"Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax","volume":"108","author":"Rausch","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.trecan.2025.06.002_bb0165","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0170","series-title":"A Phase 1B study of the MENIN-KMT2A inhibitor JNJ-75276617 in combination with venetoclax and azacitidine in relapsed\/refractory acute myeloid leukemia with alterations in KMT2A OR NPM1 [abstract S133]","author":"Wei","year":"2024"},{"key":"10.1016\/j.trecan.2025.06.002_bb0175","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2024-198218","article-title":"Ziftomenib combined with intensive induction (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2024-207072","article-title":"Phase 1b study of menin-KMT2A inhibitor bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations","volume":"144","author":"Recher","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0185","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib combined with venetoclax\/azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: interim Phase 1a results from KOMET-007","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0190","series-title":"Phase 1B study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 MUTATED OR KMT2A REARRANGED AML: interim results of dose escalation from the beataml consortium [abstract S134]","author":"Zeidner","year":"2024"},{"key":"10.1016\/j.trecan.2025.06.002_bb0195","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2024024008","article-title":"How I treat acute myeloid leukemia with differentiation therapy","volume":"145","author":"Issa","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0200","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.06.002_bb0205","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/blood-2024-202042","article-title":"Discovery of BTC-86, a novel second-generation menin-MLL inhibitor to overcome the acquired resistance in MEN1 for R\/R acute leukemia","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0210","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0215","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.002_bb0220","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between mammalian MLL complexes dictates response to menin\u2013MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.trecan.2025.06.002_bb0225","article-title":"Targeting the Menin\u2013KMT2A interaction in leukemia: lessons learned and future directions","author":"Perner","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2025.06.002_bb0230","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood-2024-208887","article-title":"Discerning the landscape of menin inhibitor resistance","volume":"144","author":"Bourgeois","year":"2024","journal-title":"Blood"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580332500144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580332500144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:54:48Z","timestamp":1778882088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240580332500144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S240580332500144X"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.06.002","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in menin inhibition in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}